News & Updates

In the interim analysis of the phase III BRIGHT-2 study, adding the CDK4/6 inhibitor bireociclib to fulvestrant prolongs progression-free survival (PFS) in Chinese women with HR+/HER2- advanced breast cancer (ABC) who progressed on or after endocrine therapy (ET).

In women being treated for cervical cancer, chemotherapy and radiotherapy appear to have a substantial and lasting negative effect on sexual health, including satisfaction and desire, as shown in a descriptive cross-sectional study conducted in Brazil.

Adding metformin to letrozole and abemaciclib does not cause serious safety concerns and may even encourage favourable responses among patients with oestrogen receptor (ER)-positive recurrent endometrial cancer (EC), according to a phase II study presented at SGO 2025.

The use of transdermal oestradiol (tE2) or oestrogen patches helps suppress testosterone and prostate-specific antigen (PSA) in men with locally advanced prostate cancer, with similar efficacy to that of luteinizing hormone-releasing hormone (LHRH) analogues, reports a study presented at EAU 2025.

Long-term prostate cancer survivors report high levels of self-efficacy, but the contrary is true for subgroups who are facing some challenges, a study presented at EAU 2025 has found.